MedPath

ABBVIE

ABBVIE logo
🇺🇸United States
Ownership
-
Established
2013-01-01
Employees
-
Market Cap
$346B
Website
http://www.abbvie.com

Neurocrine Biosciences Initiates Phase 1 Trial for Long-Acting CAH Treatment NBIP-01435

Neurocrine Biosciences has launched a Phase 1 first-in-human clinical study evaluating NBIP-01435, a long-acting corticotropin-releasing factor type 1 receptor antagonist for congenital adrenal hyperplasia treatment.

AbbVie Acquires Capstan Therapeutics for $2.1 Billion to Advance In Vivo CAR-T Technology for Autoimmune Diseases

AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1 billion to gain access to CPTX2309, a potential first-in-class treatment for autoimmune diseases currently in Phase 1 trials.

AbbVie Acquires In Vivo CAR-T Developer Capstan Therapeutics for Up to $2.1 Billion

AbbVie has agreed to acquire cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion in cash, gaining access to innovative in vivo CAR-T technology.

FDA Accepts Review of SKINVIVE by Juvéderm for Neck Line Treatment Expansion

Allergan Aesthetics has received FDA acceptance for review of its supplemental premarket approval application to expand SKINVIVE by Juvéderm's indication from cheek smoothness to include neck line treatment.

Simcere Zaiming Initiates US Phase 1 Trial of Trispecific Antibody SIM0500 for Relapsed/Refractory Multiple Myeloma

Simcere Zaiming has dosed the first US patient in a Phase 1 trial of SIM0500, a trispecific antibody targeting GPRC5D, BCMA, and CD3 for relapsed/refractory multiple myeloma treatment.

Avalo Therapeutics Appoints Rita Jain to Board as AVTX-009 Phase 2 Trial for Hidradenitis Suppurativa Progresses

Avalo Therapeutics has appointed Rita Jain, M.D., a rheumatologist with over two decades of biopharmaceutical leadership experience, to its Board of Directors.

AbbVie's Qulipta Demonstrates Superior Tolerability and Efficacy Over Topiramate in Head-to-Head Migraine Prevention Trial

AbbVie's migraine prevention drug Qulipta showed significantly lower discontinuation rates compared to topiramate in a late-stage head-to-head trial, with only 12.1% of patients stopping treatment versus 29.6% for the generic drug at 24 weeks.

Bavarian Nordic Sells Priority Review Voucher for $160 Million Following Chikungunya Vaccine Approval

Bavarian Nordic announced the sale of its Priority Review Voucher for $160 million, awarded following FDA approval of its chikungunya vaccine VIMKUNYA in February 2025.

AbbVie's Atogepant Demonstrates Superior Tolerability and Efficacy Over Topiramate in Phase 3 Migraine Prevention Trial

AbbVie's Phase 3 TEMPLE study shows atogepant (QULIPTA/AQUIPTA) achieved significantly fewer treatment discontinuations due to adverse events compared to topiramate for migraine prevention.

Senate Republicans Drop Orphan Drug Exemptions from Trump Tax Bill, Dealing Blow to Rare Disease Drug Development

Senate Republicans excluded the Orphan Cures Act from their version of Trump's "One Big Beautiful Bill Act," removing provisions that would have exempted multi-indication orphan drugs from Medicare price negotiations.

© Copyright 2025. All Rights Reserved by MedPath